November 4, 2024
Professor Michael Weller, a leading Neuro-oncologist who currently serves as the Chairman of the Department of Neurology at the University Hospital in Zurich, Switzerland and as the National Coordinating Investigator for CNS Pharmaceuticals' potentially pivotal study of Berubicin, discusses the unmet need in glioblastoma multiforme (GBM), the current treatment landscape and the potential for Berubicin to provide a solution for this devasting disease.
October 10, 2024
Members of the CNS Management Team and leading Neuro-Oncologist and Key Opinion Leader, Dr. Samuel Goldlust discuss the unmet need in glioblastoma multiforme (GBM) and the CNS opportunity
Access, Ideas, Clarity
A leading virtual platform providing investors with direct access to innovative companies, management teams and thought leaders
KOL COnnect
September 18, 2024
GRI Bio Participates in Virtual Investor KOL Connect Segment Featuring Dr. Helen Parfrey, Respiratory Consultant at the Royal Papworth Hospital and Affiliated Assistant Professor at the University of Cambridge
August 19, 2024
Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer